UiPath (NYSE:PATH) PT Lowered to $25.00 at Scotiabank

UiPath (NYSE:PATHGet Free Report) had its target price cut by analysts at Scotiabank from $30.00 to $25.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “sector perform” rating on the healthcare company’s stock. Scotiabank’s price target points to a potential upside of 107.13% from the stock’s previous close.

Several other equities analysts have also recently issued reports on PATH. Barclays lifted their price objective on shares of UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, March 15th. TD Cowen boosted their target price on UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, March 14th. DA Davidson lifted their price target on UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, March 14th. Canaccord Genuity Group upped their price objective on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Mizuho lifted their target price on shares of UiPath from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Fifteen research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.24.

Read Our Latest Analysis on PATH

UiPath Price Performance

NYSE:PATH opened at $12.07 on Wednesday. UiPath has a 12 month low of $11.71 and a 12 month high of $27.87. The firm has a market capitalization of $6.87 billion, a PE ratio of -71.00 and a beta of 1.01. The business’s 50-day moving average is $20.13 and its two-hundred day moving average is $22.06.

UiPath (NYSE:PATHGet Free Report) last released its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The firm had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. Equities analysts anticipate that UiPath will post -0.04 EPS for the current year.

Insider Activity

In related news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total value of $866,400.00. Following the transaction, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 96,000 shares of company stock valued at $2,023,440. Insiders own 22.37% of the company’s stock.

Institutional Investors Weigh In On UiPath

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal London Asset Management Ltd. grew its stake in shares of UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after purchasing an additional 7,742 shares during the period. Swiss National Bank raised its holdings in UiPath by 4.9% during the 4th quarter. Swiss National Bank now owns 1,211,500 shares of the healthcare company’s stock worth $30,094,000 after buying an additional 56,600 shares during the period. Vestmark Advisory Solutions Inc. acquired a new position in UiPath in the 4th quarter worth $15,543,000. O Shaughnessy Asset Management LLC bought a new position in shares of UiPath during the 3rd quarter worth approximately $203,000. Finally, Invesco Ltd. increased its stake in UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after buying an additional 10,863 shares during the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

About UiPath

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Articles

Analyst Recommendations for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.